The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn’s disease

References

• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389(10080):1741–1755. doi:10.1016/S0140–6736(16)31711–1.
   PubMed Web of Science ®Google Scholar
• Adegbola SO, Sahnan K, Warusavitarne J, et al. Anti-TNF therapy in crohn’s disease. Int J Mol Sci. 2018;19(8):2244. doi:10.3390/ijms19082244.
   PubMed Web of Science ®Google Scholar
• Petitdidier N, Beaugerie L, Carbonnel F, et al. Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: a 12-month prospective observational cohort study. Clin Res Hepatol Gastroenterol. 2020;44(4):609–618. doi:10.1016/j.clinre.2019.11.008.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S. Loss of response to anti-tumor necrosis factors: what is the next step? Dig Dis. 2014;32(4):384–388. doi:10.1159/000358142.
   PubMed Web of Science ®Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674–684. doi:10.1038/ajg.2011.60.
   PubMed Web of Science ®Google Scholar
• Moore C, Corbett G, Moss AC. Systematic review and Meta-Analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis. 2016;10(5):619–625. doi:10.1093/ecco-jcc/jjw007.
   PubMed Web of Science ®Google Scholar
• Nakase H, Motoya S, Matsumoto T, DIAMOND study group., et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with crohn’s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017;46(9):873–882. doi:10.1111/apt.14318.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329.e3. doi:10.1053/j.gastro.2015.02.031.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–971. doi:10.1038/ajg.2013.12.
   PubMed Web of Science ®Google Scholar
• Nguyen DL, Flores S, Sassi K, et al. Optimizing the use of anti-tumor necrosis factor in the management of patients with crohn’s disease. Ther Adv Chronic Dis. 2015;6(3):147–154. doi:10.1177/2040622315579621.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, UK Inflammatory Bowel Disease Pharmacogenetics Study Group., et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353. doi:10.1016/S2468–1253(19)30012–3.
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with crohn’s disease. Gastroenterology. 2014;146(3):681–688.e1. doi:10.1053/j.gastro.2013.11.024.
   PubMed Web of Science ®Google Scholar
• Johnson CM, Dassopoulos T. Update on the use of thiopurines and methotrexate in inflammatory bowel disease. Curr Gastroenterol Rep. 2018;20(11):53. doi:10.1007/s11894–018–0658–1.
   PubMedGoogle Scholar
• Afif W, Loftus EV, Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–1139. doi:10.1038/ajg.2010.9.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Feagan BG, Wolf DC, et al. Therapeutic drug monitoring of tumor necrosis factor antagonists in crohn disease: a theoretical construct to apply pharmacokinetics and guidelines to clinical practice. Inflamm Bowel Dis. 2021;27(8):1346–1355. doi:10.1093/ibd/izaa265.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Vermeire S, Lambrecht G, GETAID., et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and Corticosteroid-Free remission in patients with active luminal crohn’s disease. Gastroenterology. 2018;154(5):1343–1351.e1. doi:10.1053/j.gastro.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Kelly OB, Donnell SO, Stempak JM, et al. Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(7):1202–1209. doi:10.1097/MIB.0000000000001126.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–1588.e3. doi:10.1016/j.cgh.2017.03.031.
   PubMed Web of Science ®Google Scholar
• Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021;116(10):2014–2025. doi:10.14309/ajg.0000000000001396.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, IBD guidelines eDelphi consensus group., et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi:10.1136/gutjnl-2019–318484.
   PubMed Web of Science ®Google Scholar
• Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003. doi:10.1097/MIB.0000000000000156.
   PubMed Web of Science ®Google Scholar
• Bojic D, Bodger K, Travis S. Patient reported outcome measures (PROMs) in inflammatory bowel disease: new data. J Crohns Colitis. 2017;11(suppl_2):S576–S585.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, International Organization for the Study of IBD., et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(9):1655–1668.e3. doi:10.1016/j.cgh.2019.03.037.
   PubMed Web of Science ®Google Scholar
• Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with crohn’s disease compared with reactive monitoring. Gastroenterology. 2019;157(4):985–996.e2. doi:10.1053/j.gastro.2019.06.003.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Baert F, Laharie D, et al. Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of crohn’s disease. Clin Gastroenterol Hepatol. 2020;18(3):637–646.e11. doi:10.1016/j.cgh.2019.05.029.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019;35(4):302–310. doi:10.1097/MOG.0000000000000536.
   PubMed Web of Science ®Google Scholar
• Cao WT, Huang R, Jiang KF, et al. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: a systematic review. World J Gastroenterol. 2021;27(9):886–907. doi:10.3748/wjg.v27.i9.886.
   PubMed Web of Science ®Google Scholar
• Kantasiripitak W, Verstockt B, Alsoud D, et al. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. Br J Clin Pharmacol. 2021;87(10):3776–3789. doi:10.1111/bcp.14785.
   PubMed Web of Science ®Google Scholar
• Kang B, Choi SY, Choi YO, et al. Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric crohn’s disease. J Crohns Colitis. 2019;13(2):189–197. doi:10.1093/ecco-jcc/jjy155.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rakowsky S, Rivera C, et al. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in crohn’s disease. Inflamm Bowel Dis. 2018;24(10):2266–2271. doi:10.1093/ibd/izy132.
   PubMed Web of Science ®Google Scholar
• Franco DL, Click B. Proactive versus reactive therapeutic drug monitoring of infliximab in crohn’s disease: is the juice worth the squeeze? Inflamm Bowel Dis. 2020;26(1):112–113. doi:10.1093/ibd/izz114.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12(7):804–810. doi:10.1093/ecco-jcc/jjy039.
   PubMed Web of Science ®Google Scholar
• Ungar B, Engel T, Yablecovitch D, et al. Prospective observational evaluation of time-Dependency of adalimumab immunogenicity and drug concentrations: the POETIC study. Am J Gastroenterol. 2018;113(6):890–898. doi:10.1038/s41395–018–0073–0.
   PubMed Web of Science ®Google Scholar
• Burgess CJ, Reilly C, Steward-Harrison L, et al. Utility of proactive infliximab levels in paediatric crohn’s disease. Arch Dis Child. 2019;104(3):251–255. doi:10.1136/archdischild-2018–315100.
   PubMed Web of Science ®Google Scholar